KR20000022489A - Method for producing recombinant adenovirus - Google Patents

Abstract

PURPOSE: Provided is a novel method for producing recombinant Adenovirus. And purified virus preparations produced by processes of the method is also provided. CONSTITUTION: Provided is a method for producing recombinant Adenovirus by which viral DNA is introduced in a packaging cell culture and the viruses produced are harvested after by ultrafiltration, gel permeation chromatography or ion exchange chromatography, after liberation of at least 50% of virus in the supernatant. The viruses produced and their use are also provided.

Description

Method for producing recombinant adenovirus

Adenoviruses show particularly advantageous properties for use as gene delivery vectors in gene therapy. In particular, they have a fairly broad host spectrum, can infect resting cells, do not integrate into the genome of infected cells, and to date have not been associated with major pathologies in humans. Adenoviruses are therefore responsible for the use of these genes in muscle [Ragot et al. m Nature 361 (1993) 647], liver [Jaffe et al., Nature genetics 1 (1992) 372], nervous system (Akli et al., Nature genetics 3 (1993) 224) and the like. Has been used in.

Adenovirus is a linear double stranded DNA of about 36 (kilobase) kb in size. Their genomes, in particular, include reverse repeats (ITR), capsidized sequences (Psi), early genes and late genes at each end. The main early genes are in the E1, E2, E3 and E4 regions. Among these, genes particularly in the E1 region are essential for virus propagation. The major late genes are in the L1 to L5 regions. The genome of the Ad5 adenovirus is fully sequenced and accessible on the database (especially Genebank M73260). Similarly, some or even all of the other adenovirus (Ad2, Ad7, Ad12, etc.) genomes were sequenced.

In order to use them in gene therapy, various vectors derived from adenoviruses into which various therapeutic genes have been introduced have been produced. In each of these constructs, the adenovirus is modified so that it cannot replicate in infected cells. Thus, the constructs described in the prior art are adenoviruses which delete the E1 region essential for viral replication and insert heterologous DNA sequences at this level (Levrero et al., Gene 101 (1991) 195; Gosh-Choudhury et al., Gene 50 (1986) 161] Moreover, in order to enhance the properties of the vector, it has been proposed to create other deletions or modifications in the adenovirus genome. Thus, heat-sensitive mutations have been introduced into the ts125 mutant, which makes it possible to inactivate 72 kDa DNA binding protein (DBP) (Van der Vlist et al., 1975). Other vectors include deletion of other regions, E4 regions, which are essential for viral replication and / or propagation. The E4 region is actually involved in regulating expression of late genes, stability of late nuclear RNA, abolition of expression of host cell proteins and the efficacy of viral DNA replication. Thus, adenovirus vectors that have deleted the E1 and E4 regions retain transcriptional background noise and very reduced expression of viral genes. Such vectors are described, for example, in applications WO 94/28152, WO 95/02697, PCT / FR96 / 00088. In addition, vectors carrying modifications at the IVa2 gene level have also been described (WO 96/10088).

Recombinant adenoviruses described in the literature are generated from different adenovirus serotypes. In fact, there are a variety of adenovirus serotypes that vary somewhat in structure and character, but they show comparable genetic makeup. More specifically, the recombinant adenovirus may be of human or animal origin. With respect to adenoviruses of human origin, there are preferably those classified into the C group, in particular those of type 2 (Ad2), 5 (Ad5), 7 (Ad7) or 12 (Ad12). Among the various adenoviruses of animal origin, preferably all strains of dog origin and in particular of CAV2 adenoviruses (for example, Manhattan strain or A26 / 61 (ATCC VR-800). Other adenoviruses of animal origin Is described in application WO 94/26914, which is incorporated herein by reference.

In a preferred embodiment of the invention, the recombinant adenovirus is a C group human adenovirus. More preferably, it is Ad2 or Ad5 adenovirus.

Recombinant adenoviruses are produced in capsidated lines, ie cell lines that can complement trans with one or more functions missing in the recombinant adenovirus genome. One such cell line is cell line 293, for example, in which a portion of the adenovirus genome is integrated. More precisely, cell line 293 is a serotype 5 adenovirus (Ad5) genome comprising a left ITR, a capsidized region, an E1 region including E1a and E1b regions, a region encoding a pIX protein and a region encoding a pIVa2 protein. Human embryonic kidney cell line containing the left end of the (about 11 to 12%). This cell line can trans-complement recombinant adenoviruses lacking the El region, ie, all or part of the El region, and can produce high titers of viral stock. This cell line can also produce virus stocks that further include heat-sensitive E2 mutations at acceptable temperatures (32 ° C.). Other cell lines capable of complementing the El region are in particular human lung cancer cells A549 (WO 94/28152) or human retinal blasts [Hum. Gen. Ther. (1996) 215). Moreover, cell lines have been described that can complement the functions of several species of adenoviruses. In particular, cell lines capable of complementing the E1 and E4 regions are described in Yeh et al., J. Virol. 70 (1996) 559; Cancer Gen. Ther. 2 (1995) 322; Krougliak et al., Hum. Gen. Ther. 6 (1995) 1575] and cell lines capable of complementing the El and E2 regions (WO 94/28152, WO 95/02697, wO / 27071).

Recombinant adenoviruses are produced by introducing viral DNA into the capsid, followed by lysis of cells about 2 or 3 days (kinetics of the adenovirus cycle is 24 to 36 hours). After cell lysis, the recombinant virus particles are separated by cesium chloride gradient centrifugation.

To carry out this process, the introduced viral DNA may be a complete recombinant viral genome transfected into cells, optionally constructed in bacteria (WO 96/25506) or yeast (WO 95/03400). Viral DNA may also be introduced in the form of fragments, each carrying a homology region that allows the viral genome to be reconstructed by homologous recombination between the various fragments, after each introduction into a portion of the recombinant viral genome and into the capsidized cells. Thus, conventional methods for the production of adenoviruses include the following steps: infecting cells (eg, cells 293) with virus prestock in an amount of 3 to 5 virus particles per cell in a culture dish, or (Infection redundancy (MOI) = 3-5), infected with viral DNA. The incubation is then continued for 40 to 72 hours. The virus is then released from the nucleus by cell lysis, usually by several successive thawing cycles. The obtained cell lysate is then centrifuged at low speed (2000-4000 rpm) and the supernatant (cleared cell lysate) is centrifuged in two steps in the presence of cesium chloride:

First high speed centrifugation for 1.5 h in two cesium chloride layers of density 1.25 to 1.40 flanking virus density (1.34) to separate viruses from proteins in medium;

A second long-term gradient centrifugation (10 to 40 hours depending on the rotor used), which constitutes a substantially single virus purification step.

Generally, after the second centrifugation step, the viral band is dominant. Nevertheless, two microscopic and less dense bands showed by electron microscopy that they were hollow or destroyed virus particles for denser bands and viral subunits (peptone, hexone) for less dense bands. Is observed. After this step, the virus is collected in a centrifuge tube by perforation using a needle and the cesium is removed by dialysis or desalting.

Although the level of purity obtained is satisfactory, this type of fixation nevertheless has certain disadvantages. In particular, this process is based on the use of cesium chloride which is reactive in humans that is incompatible with therapeutic uses. For this reason, it is inevitable to remove cesium chloride at the end of the purification. This process also has other disadvantages, which are mentioned later, which limit its use on an industrial scale.

In order to overcome this problem, it has been proposed to purify the virus using chromatography after dissolution without using cesium chloride gradient. Thus, a paper by Huyghe et al. [Hum. Gen. Ther. 6 (1996) 1403 describe different types of studies of chromatography introduced in the purification of recombinant adenoviruses. This paper describes, in particular, the purification of recombinant adenoviruses using weak anion-exchange chromatography (DEAE). Previous studies have already described the use of this type of chromatography for this purpose (Klemperer et al., Virology 9 (1959) 536; Philipson L., Virology 10 (1960) 459: Haruna et al., Virology 13 (1961) 264]. The results presented in the paper by Huyghe et al. Demonstrate the very mediocre efficacy of the recommended ion exchange chromatography procedure. Thus, the analytical power obtained is average and the authors believe that viral particles are present in several chromatographic peaks; Low yield (viral particle yield: 67%; infected particle yield: 49%); And suggest that the viral preparation performed following this chromatography step is not pure. In addition, it is necessary to pretreat the virus with various enzymes / proteins. This same paper also describes a study on the use of gel permeation chromatography demonstrating very poor analysis and very low yields (15-20%).

The present invention relates to a novel method for producing a recombinant adenovirus. The present invention also relates to purified virus preparations produced according to the present process.

1: Study of stability of adenovirus purified according to Example 4. FIG.

2: HPLC (reverse phase) analysis of adenovirus purified according to Example 4. FIG. Comparison with the adenovirus of Example 3.

3: Release kinetics of adenovirus Ad-βGal in cell 293 supernatant measured by semiquantitative PCR and plaque assay.

4: Elution profile for Source Q15 of ultrafiltered adenovirus supernatant (Example 5.1).

Figure 5: Ressource Q HPLC analysis of virus peaks obtained by chromatography on Source Q15 resin of ultrafiltered adenovirus supernatant (Example 5.1).

Figure 6: (A) Elution profile for Source Q15 resin of ultrafiltered Ad-APOA1 adenovirus supernatant (Example 5.3); And (B) HPLC (Resource Q) analysis of the virus peak obtained.

Figure 7: (A) Elution profile for Source Q15 of ultrafiltered Ad-TK adenovirus supernatant (Example 5.3). HPLC (Resource Q) analysis of the various virus fractions obtained (start and end of peak): (B) Fraction F2, middle of peak; (C) fraction F3, limit of peaks; (D) Fraction F4, end of peak.

8: Elution profile for Mono Q resin of concentrated supernatant of adenovirus producing cell culture (Example 5.4). BG25F1: Virus supernatant concentrated and purified in cesium. BG25C: concentrated infected supernatant.

9: Elution profile for POROS HQ gel of concentrated supernatant of adenovirus producing cell culture (Example 5.4). BG25F1: Virus supernatant concentrated and purified in cesium. BG25C: concentrated infected supernatant.

10A and B: Gel Permeation Tablet Profile for S1000HR / Superdex 200HR of Ultrafiltered Adenovirus Supernatant (Example 6).

11: Analysis by electron microscopy of adenovirus stocks purified according to the invention.

12: Analysis by electron microscopy of density 1.27 virus bands.

Common molecular biology techniques

Methods commonly used in molecular biology, such as preliminary extraction of plasmid DNA, centrifugation of plasmid DNA in a cesium chloride gradient, electrophoresis of agarose or acrylamide gels, purification of DNA fragments by electrolysis, phenols of proteins Or phenol-chloroform extraction, ethanol or isopropanol precipitation of DNA in saline media, transformation in Escherichia coli and the like are well known to those skilled in the art and described in Maniatis T. et al., “Molecular Cloning, a Laboratory Manual ", Cold Spring Haebor Laboratory, Cold Spring Harbor, NY, 1982; Ausubel F.M. et al., (eds), "Current Protocols in Molecular Biology", John Wiley & Sons, New York, 1987.

Phages of pBR322 and PUC type plasmids and the M13 series are of commercial origin (Bethesda Research Laboratories). For ligation, DNA fragments are separated by size by agarose or acrylamide gel electrophoresis, extracted with a phenol or phenol / chloroform mixture, precipitated with ethanol and phage T4 DNA ligase (Biolabs as recommended by the supplier). Culture in accordance with the supplier's specifications in the presence of Filling out the 5 'end extends in accordance with the supplier's specifications. It can be performed with Klenob fragment of E. coli DNA polymerase I (Biolabs). Breakage of the extending 3 'end is carried out in the presence of phage T4 DNA polymerase (Biolabs) used according to the manufacturer's recommendations. Destruction of the extending 5 'end is carried out by controlled treatment with S1 nucleases.

In vitro site-induced mutagenesis by synthetic oligodioxynucleotides is described by Taylor et al. Nucleic Acids Res. 13 (1985) 8749-8764 can be performed using a kit contributed by Amersham. So-called PCR techniques [Ref. Polymerase-catalyzed Chain Reaction, Saiki R.K. et al., Science 230 (1985) 1350-1354; Mullis K.B. and Faloona F.A. Meth. Enzym. 155 (1987) 335-350 can be carried out using a DNA thermal cycler (Perkin Elmer) according to the manufacturer's specifications. Diversification of nucleotide sequences is described by Sanger et al., Proc. Natl. Acad. Sci. USA, 74 (1977) 5463-5467, by a kit contributed by Amersham.

Example

Example 1: Capsidation of Cell Lines

Capsidated cells used within the framework of the present invention can be obtained from cell lines that can be infected by adenoviruses and are compatible with therapeutic purposes. These are more preferably selected from the following cell lines:

293 cell lines:

The 293 cell line has the left end of the serotype 5 adenovirus (Ad5) genome, including the left ITR, the encapsidation region, the E1 region comprising E1a and E1b, the region encoding the pIX protein and the region encoding the pIVa2 protein (about 11 To 12%) in human embryonic kidney cell lines. J. Gen. Virol. 36 (1977) 59). Such cell lines can trans complement the recombinant adenovirus that is defective for the El region, ie lacks all or part of the El region, and can produce high titers of viral stock.

A459 cell line

Cells complementing the adenovirus El region are constructed from A549 cells (Imler et al., Gene Ther. (1996) 75). These cells lack the left ITR and contain a limited fragment of the El region located under the control of an inducible promoter.

HER cell line

Human embryonic retinal (HER) cells are infected with adenovirus (Byrd et al., Oncogene 2 (1998) 477). Adenovirus encapsulated cells prepared from such cells are described, for example, in the application WO 94/28152 or in Fallaux et al. (Hum. Gene Ther. (1996) 215). More specifically, reference may be made to cell line 911 comprising the El region of the Ad5 adenovirus genome, nucleotide 5789 at nucleotide 79 integrated into the genome of HER cells. This cell line allows for virus production that is binding to the El region.

IGRP2 cells

IGRP2 cells are cells obtained under the control of an inducible promoter by incorporation of functional units of the E4 region from cell 293. Such cells allow the production of viruses that are missing for the El and E4 regions (Yeh et al., J. Virol (1996) 70).

-VK cells

VK cells (VK2-20 and VK10-9) are cells obtained by integration of the entire E4 region and the region encoding the pIX protein under the control of an inducible promoter from cell 293. Such cells allow the generation of viruses that are missing for the El and E4 regions (Krougliak et al., Hum. Gene Ther. 6 (1995) 1575).

293E4 cells

293E4 cells are cells obtained by integration of the entire E4 region from cell 293. Such cells allow the generation of viruses that are missing for the El and E4 regions (WO 95/02597; Cancer Gene Ther. (1995) 322).

Example 2: Viruses Used

Viruses produced in the following example situations are described in E. Adenoviral containing gene encoding E. coli LacZ marker gene (Ad-βGal), Huffs virus thymidine kinase (Ad-TK), adenovirus and apolipoprotein A1 containing gene encoding human p53 tumor suppressor protein It is a virus that encrypts (Ad-apoAI). Such viruses are derived from the Ad5 serotype and have the following structure:

A deletion in the El region comprising, for example, 3446 (Sau3a region) at nucleotide 382 (HinfI site).

Cassette for gene expression under the control of the RSV or CMV promoter, inserted at the level of deletion.

Deletion in the E3 region.

The construction of such viruses is described in WO 94/25073, WO 95/14102, FR 95/01632, Stratford-Perricaudet et al., J. Clin. Invest (1992) p626. It is understood that viruses carrying other constructs, particularly other heterologous genes and / or other deletions (eg, E1 / E4 or E1 / E2), can be produced according to the methods of the present invention.

Example 3: Generation of Virus by Cell Lysis

This example regenerates previous techniques for virus production in lysing capsidated cells to recover the virus produced.

Cells 293 with 80 to 90% confluence in culture dishes with prestock of Ad-βGal or Ad-TK virus (Example 2) at an amount of 3 to 5 viruses per cell (duplication of infection MOI = 3 to 5) Infect. Incubation is continued for 40 to 72 hours, and the timing of obtaining is determined by observing cells that are rounded under the microscope and are more refractive and adhere to the culture support more and more weakly. In the literature, the kinetics of virus cycles last for 24 to 36 hours.

At the level of laboratory production, the cells are harvested prior to separation to remove the infection medium at the time of harvest without losing the cells and then to obtain them in a minimum volume (concentration factor is about 10 to 100 times depending on the culture size). It is important.

Virus is then released from the nucleus by 3 to 6 consecutive thaw cycles (ethanol-dried at −70 ° C., water bath at 37 ° C.).

The cell lysate obtained is then centrifuged at low speed (2000-4000 rpm) and then the supernatant (clear cell lysate) is purified by ultrafiltration on a cesium chloride gradient in two steps:

First rapid ultrafiltration of two cesium layers 1.25 and 1.40 for 1.5 hours, 35000 rpm, rotor sw 41 to flank the virus density (1.34) to remove the virus from the protein in the medium; The rotor may be a "swinging" rotor (Sw28, Sw41 Beckman) or a fixed angle rotor (Ti 45, Ti70, Ti 70.1 Beckman) depending on the volume to be treated.

A second, longer gradient gradient ultrafiltration (10 to 40 hours depending on the rotor used), for example 18 hours at 35000 rpm in a sw 41 rotor constituting substantially alone virus purification. Viruses exist in a linear gradient in equilibrium at a density of 1.34.

Generally at this stage, viral bands prevail. Nevertheless, two fine and darker bands are often observed and examination by electron microscopy has demonstrated that this is an empty or broken virus and the virus subunits (Fenton, Hexon) for the least dark bands. After this step, the virus is obtained by penetrating with a needle and cesium is removed by dialysis or desalting on G25.

Example 4: Generation of Virus in Supernatant

This example describes a virus production experiment by recovery of the following natural releases. The virus is collected by ultrafiltration and purified by cesium chloride.

4.1. process

In the present method, unlike Example 3, cells are not collected only after 40 to 72 hours after infection, but are cultured for 8 to 12 days without performing a freeze-thaw cycle to obtain whole cell lysate. The virus is present in the supernatant.

The supernatant is clarified through filtration on a depth filter of tapered porosity (10 μm / 1.0 μm / 0.8-0.2 μm).

The virus has a size of 0.1 μm and at this stage no loss of virus due to retention on the filter at the lowest porosity (0.22 μm) is observed.

Once clarified, the supernatant is concentrated via tangential ultrafiltration on a Millipore spiral membrane with a cut of 300 kDa.

In the experiments reported herein, the concentration factor is expressed as the boundary volume of the system which is 100 ml. This system can be used to concentrate the supernatant volume of 4 to 20 liters to obtain a concentrate volume of 100 ml to 200 ml, corresponding to a concentration factor of 20 to 100 times without difficulty.

The concentrate is filtered over 0.22 μm and then purified by centrifugation on cesium chloride as described in Example 3, followed by the dialysis step.

4.2. result

water

Although intracellular viral tubes (Example 3) sometimes have a cloudy form with viral banded clots (lipids, proteins), virus preparations obtained after the first centrifugation step on cesium chloride by the process of the present invention are supernatant. It has a virus band already well separated from impurities in the sustaining medium. High-resolution liquid chromatography analysis on a Resource Q column (Comparative Example 5) also shows nucleic acid impurities (OD 260/280 ratio greater than or equal to 1.8) and protein impurities in the purity of the starting material obtained by ultrafiltration of the infected supernatant. (OD 260/280 ratio less than 1) shows this result.

Virus Stability in Supernatant at 37 ° C

By plaque assay, aliquots of infectious culture supernatants collected at various incubation times after infection at 37 ° C. are titrated to observe the stability of the virus. It is shown below:

Ad-TK Virus:

Titration after 10 days of infection = 3.5 × 10 ⁸ pfu / ml

Proper dose 20 days after infection = 3.3 x 10 ⁸ pfu / ml Ad-βGal virus

Titration 8 days post infection = 5.8 x 10 ⁸ pfu / ml

Titration 9 days after infection = 3.6 x 10 ⁸ pfu / ml

Titration after 10 days of infection = 3.5 × 10 ⁸ pfu / ml

Titration 13 days after infection = 4.1 x 10 ⁸ pfu / ml

Titer 16 days after infection = 5.5 x 10 ⁸ pfu / ml

The results obtained show that, at least 20 days after infection, the appropriate amount of supernatant is stable within the range of precision of the assay. 1 also shows that in elution buffer, the virus is stable for at least 8 months at −80 ° C. and −20 ° C. FIG.

Specific infectivity of the preparation

These parameters corresponding to the ratio of virus particle number to pfu number measured by HPLC provide information regarding the infectivity of the virus preparation. According to FDA's recommendation, this should be less than 100. These parameters are measured as follows: Two classes of culture flasks containing cells 293 are simultaneously infected side by side with the same virus prestore under the same conditions. This experiment is performed for recombinant Ad-βgal adenovirus and then this experiment is repeated for Ad-TK adenovirus. For each adenovirus, a series of flasks were collected 48 hours after infection and this is considered the production of purified intracellular virus on cesium gradient after freeze-thaw. The remaining flasks are incubated for 10 days after infection and the virus is harvested from the supernatant. The resulting tablet preparation is titrated by plaque assay and the sample is denatured in 6.4 M guanidine and the quantification of the total number of virus particles is determined by measuring the concentration of PVII protein by reverse phase HPLC on a C4 Vydac 4.6 x 50 mm column. The amount of PVII protein correlates with the number of virus particles when considering 720 PVII copies / viruses (Horwitz, Virology, second edition (1990)). Considering that the specific killing factor 1.0 unit of absorbance is 1.1 x 10 ¹² particles / ml, the method correlates with the measurement of viral particles on the preparation purified by densitometry at 260 nm.

The results obtained show that for Ad-βgal virus this ratio is 16 for supernatant virus and 45 for intracellular virus. For Ad-TK viruses, this ratio is 78 for virus harvest in the supernatant method and 80 for virus harvested by the intracellular method.

Analysis by electron microscope:

The method can detect the presence of empty particles or the absence of purified virus subunits together and assess the protein contamination of purified virus preparations or the presence of non-separable aggregates of viral particles.

Procedure: 20 μl of sample is deposited on a carbon grid and then subjected to negative staining with 1.5% uranil acetate for experiments. For the experiment, a 50 kV to 100 kV Jeol 1010 electron microscope is used.

Results: Analysis performed on the virus collected from the supernatant shows clear preparations, without impurities, aggregates and empty virus particles. It can also be distinguished from viral fibers and certain geometries. These results confirm the high quality viral particles obtained according to the present invention.

HPLC and SDS-PAGE Analysis of Protein Profiles

SDS-PAGE Analysis:

20 μl of the sample is diluted in Laemmli buffer (Nature 227 (1970) 680-685), digested at 95 ° C. for 5 min and loaded onto a Novex gel 1 mm × 10 well gradient 4-20%. After migration, the gels are stained with Coomassie Blue and analyzed on Pharmacia VDS Image Master. The analysis shows the electrophoretic profile for the virus collected from the supernatant according to literature data (Lennart Philipson, 1984 H.S. Ginsberg editors, Plenum press, 310-338).

Reverse Phase HPLC Analysis:

Figure 2 shows an overlap of three chromatograms obtained from two viral samples collected intracellularly and virus samples purified by supernatant method. Experimental conditions are as follows: Vydac column reference no. 254 Tp 5405, RPC4 4.6 x 50 mm, solvent \ A: H20 + TFA 0.07%; Solvent B: CH 3 CN + TFA 0.07%, linear gradient: T = 0 min% B = 25; T-50 min% B = 50%; Flow rate = 1 ml / min, detector = 215 nm. The chromatogram shows complete confirmation between the samples, with no difference in the relative intensity of each peak. The nature of each peak is determined by the sequence and shows that the protein presence is of all viral origin (see table below).

Peak (Min) Sympathy 19-20 Precursor PVII 21-22 Precursor PVII; Precursor PX 1-12 27-28 Precursor PVI; Precursor PX 32-33 Precursor PX 34 35-36 Mature PVII 37 Mature PVII; PVIII precursor 39-41 Mature PVI 45 pX 46 pIX

Efficiency analysis of transduction and cytotoxicity in vitro

Toxicity assays are performed by infecting HCT116 cells in 24-well plates to increase MOI and using crystal violet staining techniques, two and five days after infection, measuring the percentage of viable cells compared to non-infected controls.

The results are shown in the table below:

Adenovirus MOI = 3.0 MOI = 10.0 MOI = 30.0 MOI = 100.0 Supernatant, 2 days 91% 96% 87% 89% Supernatant, 5 days 97% 90% 10% <5%

Analysis of Transduction Efficiency

For AD-βGal adenovirus, as the concentration of viral particles increases, replication non-perceptible W162 cells cultured in 24-well plates are infected to determine the transduction efficiency of the preparation. For the same amount of viral particles deposited, cells that express beta-galactosidase activity are counted 48 hours after infection with X-gal incubated with the substrate. Each blue cell is counted as one transduction unit (TDU), and the result is multiplied by the dilution factor of the sample to obtain the concentration as the transduction unit of the sample. The concentration of virus particles: TDU concentration ratio is calculated and expressed as transduction efficiency. The results obtained show that the purified virus has good transduction efficiency in vitro.

Analysis of Intracranial Expression in Vivo

To assess the efficiency of adenoviruses according to the invention for gene delivery and expression in vivo, adenoviruses are injected into the striatum of OF1 immunocompetent mice via a stereotactic route. To this end, 1 μl of the volume of 10 ⁷ pfu of virus is injected into the following stereotactic reference point (for incision at 0 mm): fore and aft direction: +0.5; Medial lateral: 2; Depth: -3.5.

Brain is analyzed 7 days after infusion. The results obtained show high transduction efficiency: thousands of transduced cells, very strong expression in the nucleus and frequent strong dispersion in the plasma.

4.3. Dynamics of Virus Release

This example describes a study on the kinetics of adenovirus release in capsidated cell culture supernatants.

This study is performed by semiquantitative PCR with oligonucleotides complementary to the adenovirus genomic region. For this effect, linear viral DNA (1-10 ng) was incubated in the presence of Taq polymerase (Cetus) in dXTP (2 μl, 10 mM), a pair of specific oligonucleotides and 10-fold PCR buffer and under the following conditions: 30 times amplification was performed: 2 minutes at 91 ° C, 30 times (1 minute at 91 ° C, 2 minutes at annealing temperature, 3 minutes at 72 ° C), 5 minutes at 72 ° C, and then 4 ° C. PCR experiments are performed using oligonucleotide pairs of the following sequence:

Pair 1:

TAATTACCTGGGCGGCGAGCACGAT (6368)-SEQ ID NO: 1

ACCTTGGATGGGACCGCTGGGAACA (6369)-SEQ ID NO: 2

Pair 2:

TTTTTGATGCGTTTCTTACCTCTGG (6362)-SEQ ID NO: 3

CAGACAGCGATGCGGAAGAGAGTGA (6363)-SEQ ID NO: 4

Pair 3:

TGTTCCCAGCGGTCCCATCCAAGGT (6364)-SEQ ID NO: 5

AAGGACAAGCAGCCGAAGTAGAAGA (6365)-SEQ ID NO: 6

Pair 4:

GGATGATATGGTTGGACGCTGGAAG (6366)-SEQ ID NO: 7

AGGGCGGATGCGACGACACTGACTT (6367)-SEQ ID NO: 8

At various times after infection, the amount of free adenovirus in the supernatant is measured in the supernatant of cells 293 infected with Ad-βGal. The obtained result is shown in FIG. This shows that cell release begins from 5 or 6 days after infection.

It is understood that other virus measurement techniques can be used on other capsidizing columns, for the same purpose, and for adenovirus types.

Example 5: Purification of Viruses by Ultrafiltration and Ion Exchange

This example describes how adenoviruses contained in the concentrate can be purified in very high yields in direct and single ion-exchange chromatography steps.

5.1. process

In this experiment, the starting material thus consisted of the concentrate (or ultrafiltration retentate) described in Example 4. This retentate has a total protein content of 5-50 mg / ml, preferably 10-30 mg / ml in PBS buffer (pH 7.2 containing 10 mM phosphate, 150 mM NaCl).

The ultrafiltration supernatant obtained from the virus preparation was columned with Source Q 15 (Pharmacia) equilibrated in 50 mM Tris-HCl buffer pH 8.0 containing 250 mM NaCl, 1.0 mM MgCl ₂ and 10% glycerol (buffer A). Inject during. After washing with 10 column volumes of Buffer A, the adsorbed class was subjected to a linear flow rate of 60 to 300 cm / hour, preferably 12 cm / hour, using a straight NaCl gradient (250 mM-1 M) on 25 column volumes. Elute. Typical elution profiles obtained at 260 nm are shown in FIG. 4. Collect fractions containing viral particles. This corresponds to a fine symmetrical peak whose retention time is consistent with the retention time obtained using the preparation of virus particles purified by ultracentrifugation. Under the conditions described above, at least 30 mg of total protein per ml of Source Q 15 can be injected while retaining good resolution of the viral particle peak.

In a representative experiment performed with β-gal adenovirus preparation (Example 2), a total of 12.6 mg of protein was injected into a Source Q column (1 mL), ie 5 × 10 ¹⁰ PFU and 1.6 × 10 ¹⁰ TDU. Viral particle peaks collected after chromatography (3.2 mL; FIG. 5) contain 173 μg of protein and 3.2 × 10 ¹⁰ PFU and 2.3 × 10 ¹⁰ TDU. Thus, when the virus particles were purified 70 times (amount of protein), the purification yield was 64% PFU and 142% TDU (see table below).

step Concentration sample Deposition volume Collection volume yield Refinement factor Supernatant 5000 ml 5000 ml 100% - Ultrafiltration300 kd Protein: 6.3 mg / ml PFU: 2.5 x ^{10 10} / ml TDU: 8.1 x ^{10 9} / ml Particles 3.8 x ^{10 11} / ml Part / pfu ratio: 16.0 parts / tdu ratio: 47.0 5000 ml 200 ml 100% 5 Ion-Exchange Purification (Step 1) PFU: 1.0x10 ¹⁰ /㎖TDU:7.2x10 ⁹ / ㎖ particles: 2.0x10 ¹¹ / ㎖ Part / pfu ratio = 20 Part / tdu ratio = 27 2.0 ml of concentrate 3.0 ml of elution Protein = 85% PFU = 64% TDU = 140% Particle = 84% HPLC Purity = 98.4% 70 CsCl gradient PFU: 1.0x10 ¹¹ /㎖TDU:7.5x10 ¹⁰ / ㎖ particles: 2.2x10 ¹² / ㎖ Part / pfu ratio = 22 Part / tdu ratio = 29 28.3 ml of concentrate QSP28.3 ml PFU = 66% TDU = 130% Particles = 84% HPLC Purity = 98.4% 70

5.2. water

After the purification step, the collected fractions were purified by high-resolution liquid chromatography (HPLC) on a Source Q column (1 mL) in the following chromatography system to obtain purity ≧ 98% virus particles (UV detection at 260 nm). (10 mL fraction purified by chromatography described in Example 5.1 is injected into a Source Q15 column (gel 1 ml; Pharmacia) equilibrated in 50 mM Tris / HCl buffer pH 8.0 (buffer B)). After washing with 5 ml Buffer B, the adsorbed class is eluted in B buffer at a flow rate of 1 ml / min using a straight gradient of 30 ml NaCl (0-1 M). The eluted class is detected at 260 nm. This HPLC analysis (FIG. 5) also shows that the residual bovine serum albumin present in the ultrafiltration retentate is completely removed during preliminary chromatography. The content in the purified fraction is estimated to be less than 0.1%. Western blot analysis (ECL exposure; Amersham) using anti-BSA polyclonal antibodies indicates that the content of BSA in the chromatographic preparation is 100 ng or less per mg of virus.

Electrophoretic analysis of adenovirus fractions purified by chromatography is carried out on polyacrylamide gels (4-20%) under denaturing (SDS) conditions. Protein bands are represented by silver nitrate. This analysis shows that the adenovirus preparations obtained by chromatography have at least the same purity level as the ones obtained by conventional ultracentrifugation, which reveals additional protein bands that represent contaminants of the preparations by non-adenovirus proteins. Because it does not have.

The adenovirus preparation obtained by chromatography has an absorbance ratio A _{260 nm} / A _{280 nm} , which corresponds to 1.30 ± 0.05. This value, consistent with that obtained for the best preparations obtained by ultracentrifugation, indicates that the preparations do not contaminate proteins or nucleic acids.

Analysis by electron microscopy performed on the chromatography-purified Ad-βgal virus under the conditions described in Example 4.2 shows clear preparations free of contaminants, aggregates and empty virus particles (FIG. 11). In addition, cesium chloride gradient centrifugation of the present product shows a single band of density 1.30, which confirms the absence of chromatographic product contaminants by potential empty particles or capsid fractions. During purification, there is a shoulder (or second peak) at the end after the chromatographic peak for the virus, which is not collected with the main peak. Cesium chloride gradient ultracentrifugation of this fraction shows a band of density 1.27, and analysis of this fraction composition shows that it contains no nucleic acid. Analysis by electron microscopy shows that this fraction contains particles of non-uniform shape showing pores on the surface (FIG. 12). It is therefore a hollow (lacking DNA) incomplete particle. This thus demonstrates that purification of adenovirus by chromatography removed empty particles present in a small amount of preparation prior to purification.

5.3. Purification of adenoviruses containing therapeutic genes, such as genes encoding ApoA1 or thymidine kinase protein

This example describes how in the genome, adenoviruses comprising heterologous nucleic acid sequences encoding therapeutic proteins are purified in direct and single ion-exchange chromatography steps. It also shows that the chromatographic behavior of adenoviruses is consistent with the heterologous nucleic acid sequences they carry, so that the same purification process can be used for different adenoviruses carrying various heterologous nucleic acid sequences.

In a typical purification experiment, in the genome, a heterologous nucleic acid sequence encoding the ApoA1 protein (Example 2, WO 94/25073) was obtained with 18 ml of concentrated supernatant of the cell culture harvested 10 days after infection in the system described in Example 5.1. 72 mg; 1.08 × 10 ¹³ particles) was purified by chromatography (FIG. 6A). The viral particle peak collected after chromatography (14 ml; protein 1.4 mg) contains 9.98 × 10 ¹² particles, showing a particle yield of 92% and a purification factor of 51. After this purification step, the collected fractions have a purity higher than 98% (FIG. 6B) for viral particles during chromatographic analysis under the conditions described in 5.2. Electrophoretic analysis of adenovirus fractions purified by chromatography performed under the conditions described in Example 5.2 showed that these preparations had a purity level at least consistent with that of the preparations obtained by conventional ultracentrifugation and contaminating the protein. Or do not contaminate the nucleic acid.

In another typical purification experiment, an adenovirus comprising a heterologous nucleic acid sequence encoding a type 1 Huff's simplex thymidine kinase protein (Example 2, WO 95/14102) in the genome is disclosed in the system described in Example 5.1. 36 ml (180 mg protein; 4.69 × 10 ¹³ particles) of the concentrated supernatant of the cell culture were purified by chromatography (FIG. 7A). The viral particle peak collected after chromatography (20 ml; protein 5.6 mg) contains 4.28 x 10 ¹³ particles, which exhibits 91% particle yield and 32 purification factors. After this purification step, the collected fractions have a purity greater than 99% for viral particles during the chromatographic analysis under the conditions described in Example 5.2 and the absorbance ratio of 1.29 (FIGS. 7B-D). Electrophoretic analysis of adenovirus fractions purified by chromatography performed under the conditions described in Example 5.2 showed that these preparations had a purity level at least consistent with that of the preparations obtained by conventional ultracentrifugation and contaminating the protein. Or do not contaminate the nucleic acid.

5.4. Purification of Intracellular Adenovirus by Strong Anion Exchange

This example describes a method in which adenoviruses comprising heterologous nucleic acid sequences that can be directly purified in a single ion-exchange chromatography step in the genome have from lysates of capsidated cells that produce viruses.

In a typical purification experiment, adenoviruses comprising heterologous nucleic acid sequences encoding β-gal proteins in the genome were chemically lysed (1% Tween in a system described in Example 5.1 (FineLine Pilot 35 column, Pharmacia, Source 15Q resin 100 ml)). -20) is purified by chromatographing 450 ml of concentrated lysate (ie 2.5 x 10 ¹⁴ particles) of cell culture harvested only 3 days after infection. The virus particle peak (110 mL) collected after chromatography contains 2.15 × 10 ¹⁴ particles, showing a yield of 86%. After this purification step, the collected fractions have a viral particle purity greater than 98% during chromatographic analysis under the conditions described in 5.2. Electrophoretic analysis of adenovirus fractions purified by chromatography performed under the conditions described in Example 5.2 showed that these preparations had a purity level at least consistent with that of the preparations obtained by conventional ultracentrifugation and contaminating the protein. Or do not contaminate the nucleic acid.

5.5. Purification of virus by ultrafiltration and ion-exchange chromatography on various columns

This example demonstrates that the adenovirus contained in the concentrate in a single ion-exchange chromatography step with a different gel from the Source 15Q support, while working on the same separation principle, anion exchange by interacting with the quaternary amine groups of the matrix, A method that can be purified directly is described.

In a typical experiment for purification of adenoviruses, various recombinant adenoviruses (βGal, Apolipoprotein AI and TK code) are purified by chromatography on a Source Q30 gel column followed by the protocol described in Example 5.1. The results obtained show that the Source Q30 gel allows to obtain a virus preparation of 85% purity, with a yield of 70 to 100%. In addition, the results obtained indicate that Q30 has an efficiency of 1000 (expressed in the number of plates theoretically) and 0.5 to 1 x 10 ¹² vp / ml (maximum amount of virus that can be chromatographed without peak modification) for adenovirus purification. Shows. These results suggest that Source Q30 gel may be suitable for purification of recombinant adenovirus, but its properties are superior to that of Source Q15 (99% purity, 8000 efficiency and 2.5 to 5 x 10 ¹² vp / ml capacity). Show that you can't.

In another typical adenovirus purification experiment, β-Gal adenovirus is purified by chromatography on a MonoQ HR 5/5 column using the procedure described in Example 5.1. The chromatographic phases corresponding to the ultrafiltration retentate and purified virus preparation thus obtained are described in FIG. 8.

In another typical adenovirus purification experiment, β-Gal adenovirus is purified by chromatography on a poros HQ / M column using the procedure described in Example 5.1. The chromatographic phases corresponding to the ultrafiltration retentate and purified virus preparation thus obtained are described in FIG. 9.

Example 6: Purification of Virus by Ultrafiltration and Gel Permeation

This example describes how adenoviruses contained in the concentrate (ultrafiltration retentate) can be purified directly by gel permeation chromatography in very high yields.

6.1. process

200 μl of ultrafiltration retentate (ie 1.3 mg of protein) obtained in Example 4 was filled with Sephacryl S-1000SF (Pharmacia) equilibrated in PBS buffer (buffer C), for example pH 7.2 containing 150 mM NaCl. Inject into HR 10/30 column (Pharmacia). The class is fractionated and eluted with Buffer C at a flow rate of 0.5 ml / min and then detected at the outlet of the column by UV at 260 nm. Alternatively, a column filled with Sephacryl S-2000 can be used that exhibits better resolution than column Sephacryl S-1000HR for particles of 100 nm to 1000 nm under the same operating conditions.

The resolution of the two gel permeation chromatography systems described above was ultra-high on a 2 HR 10/30 column (Pharmacia) system coupled to a class equilibrated with buffer C (Sephacryl S-1000HR or S-2000 column followed by Superdex 200 HR column). It can be advantageously enhanced by chromatographic filtering supernatant (200 μl). This class is eluted with a buffer C at a flow rate of 0.5 ml / min and detected by UV at 260 nm. In this system, viral particle peaks are very well separated from the lower-molecular weight classes than in systems consisting only of Sephacryl S-1000 HR or Sephacryl S-2000 columns.

In a representative experiment, ultrafiltration retentate (200 μl, protein 1.3 mg) was chromatographed on a 2 Sephacryl S-1000HR-Superdex 200 HR 10/30 column system (FIG. 10). Chromatographic peaks containing viral particles are collected. The retention time is consistent with the retention time obtained for virus particle preparations purified by ultracentrifugation. Viral particle peak (7 mL) collected after chromatography contains 28 μg of protein and 3.5 × 10 ⁹ PFU. Analysis by analytical ion-exchange chromatography under the conditions described in Example 5.2 shows the presence of contaminating peaks remaining stronger on the analytical column, the surface area of which represents about 25% of the viral peak surface area. The 260 nm / 280 nm absorbance ratio with a value of 1.86 indicates that this fouling peak corresponds to the nucleic acid. Thus, virus particles are purified about 50 times (protein amount) and the purification yield is 85% for PFU.

Alternatively, the preparation of the virus particles (ultrafiltration or fraction in the outlet of anion-exchange chromatography) can be chromatographed on a TSK G6000 PW column (7.5 x 300 mm; TosoHaas) equilibrated with Buffer C. The class is eluted with a buffer C at a flow rate of 0.5 ml / min and detected with UV at 260 nm. In addition, the ultrafiltration supernatant (50-200 μl) was chromatographed on a two-column system coupled with a class equilibrated with Buffer C [TSK G6000 PW column (7.5 × 300 mm) followed by Superdex 200 HR column] It may be advantageous to increase the resolution of the imaging system, especially the separation of viral particle peaks from the low-molecular weight class. This class is eluted with a buffer C at a flow rate of 0.5 ml / min and detected by UV at 260 nm.

Example 7: Purification of Viruses by Ultrafiltration, Ion Exchange and Gel Permeation

The viral particle fraction derived from anion-exchange chromatography (Example 5) further improves the purity level of, for example, viral particles, while at the same time a medium that is primarily compatible with the virus preparation or suitable for its subsequent use (injection, etc.). It may advantageously be chromatographed in one of the gel permeation chromatography systems described above for packing virus particles into.

Sequence list

(1) General Information:

(i) Applicant:

(A) Name: Longfran Laura Societe Annoim

(B) Street: Avenue Lamont Along 20

(C) poetry: Anthony

(E) Country: France

(F) Zip code: 920165

(ii) Name of the Invention: Method for producing recombinant adenovirus

(iii) SEQ ID NO: 8

(iv) computer readable:

(A) Medium type: floppy disk

(B) Computer: IBM PC compatible model

(C) operating system: PC-DOS / MS-DOS

(D) Software: PatentIn Release # 1.0, version # 1.30 (EPO)

(2) Information of SEQ ID NO:

(i) sequence properties:

(A) Length: 25 base pairs

(B) Type: Nucleotide

(C) main chain type: Japanese chain

(D) mode: linear

(ii) Molecular Type: DNA

(xi) the sequence sequence of SEQ ID NO:

TAATTACCTG GGCGGCGAGC ACGAT 25

(2) Information of SEQ ID NO: 2:

(i) sequence properties:

(A) Length: 25 base pairs

(B) Type: Nucleotide

(C) main chain type: Japanese chain

(D) mode: linear

(ii) Molecular Type: DNA

(xi) the sequence sequence of SEQ ID NO: 2:

ACCTTGGATG GGACCGCTGG GAACA 25

(2) Information of SEQ ID NO: 3:

(i) sequence properties:

(A) Length: 25 base pairs

(B) Type: Nucleotide

(C) main chain type: Japanese chain

(D) mode: linear

(ii) Molecular Type: DNA

(xi) the sequence sequence of SEQ ID NO: 3:

TTTTTGATGC GTTTCTTACC TCTGG 25

(2) Information of SEQ ID NO: 4:

(i) sequence properties:

(A) Length: 25 base pairs

(B) Type: Nucleotide

(C) main chain type: Japanese chain

(D) mode: linear

(ii) Molecular Type: DNA

(xi) the sequence sequence of SEQ ID NO: 4:

CAGACAGCGA TGCGGAAGAGAGTGA 25

(2) Information of SEQ ID NO: 5:

(i) sequence properties:

(A) Length: 25 base pairs

(B) Type: Nucleotide

(C) main chain type: Japanese chain

(D) mode: linear

(ii) Molecular Type: DNA

(xi) the sequence sequence of SEQ ID NO: 5:

TGTTCCCAGC GGTCCCATCC AAGGT 25

(2) Information of SEQ ID NO: 6:

(i) sequence properties:

(A) Length: 25 base pairs

(B) Type: Nucleotide

(C) main chain type: Japanese chain

(D) mode: linear

(ii) Molecular Type: DNA

(xi) the sequence sequence of SEQ ID NO: 6:

AAGGACAAGC AGCCGAAGTA GAAGA 25

(2) Information of SEQ ID NO: 7:

(i) sequence properties:

(A) Length: 25 base pairs

(B) Type: Nucleotide

(C) main chain type: Japanese chain

(D) mode: linear

(ii) Molecular Type: DNA

(xi) the sequence sequence of SEQ ID NO: 7:

GGATGATATG GTTGGACGCT GGAAG 25

(2) Information of SEQ ID NO: 8:

(i) sequence properties:

(A) Length: 25 base pairs

(B) Type: Nucleotide

(C) main chain type: Japanese chain

(D) mode: linear

(ii) Molecular Type: DNA

(xi) the sequence sequence of SEQ ID NO: 8:

AGGGCGGATG CGACGACACT GACTT 25

The present invention describes a new method for producing recombinant adenoviruses. The process according to the invention is derived from the modification of existing processes at the production stage level and / or at the purification stage level. The process according to the invention makes it possible to obtain very high quantities and quality of virus stocks in a very rapid and industrializable manner.

One of the first aspects of the invention relates, in particular, to a method for producing a recombinant adenovirus in which the virus is harvested from the culture supernatant. Another aspect of the invention relates to a method for producing adenovirus comprising an ultrafiltration step. According to another aspect, the present invention also relates to a method for purifying recombinant adenovirus comprising an anion exchange chromatography step. The present invention also describes an improved purification method using gel permeation chromatography, optionally coupled with anion exchange chromatography. The process according to the invention makes it possible to obtain a high quality virus under production conditions which, in terms of purity, stability, morphology and infectivity, can be fully matched with industrial requirements and legislation involved in the production of therapeutic molecules in very high yields. .

In particular, in the industrial context, the process of the present invention utilizes a method of treating culture supernatants that has been demonstrated on a large scale for recombinant proteins, such as microfiltration or depth filtration, and tangential ultrafiltration. Moreover, due to the stability of the virus at 37 ° C., the process allows for better construction of the industrial stage since the collection time does not have to be accurate in half a day, in contrast to the intracellular method. Moreover, in the case of viruses with several missing regions, this ensures a maximum harvest of particularly important viruses. In addition, the process of the present invention allows easier and more accurate monitoring of production kinetics directly on homogeneous samples of the supernatant without pretreatment, which results in better reproducibility of production. The process according to the invention also makes it possible to degrade into cell lysis steps. Thus, it may be difficult to envision cell disruption by freeze-thaw cycles at the industrial level. Moreover, alternative dissolution methods (Dounce, X-press, sonication, mechanical shear, etc.) have drawbacks; These are potential producers of aerosols that are difficult to confine L2 or L3 viruses (binding levels of viruses depending on pathogenic or propagation form), and these viruses also tend to be infected by routes through the air; They produce shear forces and / or heat release that are difficult to control and reduce the activity of the formulation. Detergent use solutions for cell lysis will be required to be effective and will also require the effectiveness of detergent removal. Finally, cell lysis results in the presence of numerous cell debris in the medium making the purification more complex. In terms of virus quality, the process of the present invention potentially allows for better maturation of the virus, leading to a more homogeneous population. In particular, since the packaging of viral DNA is the final stage of the virus cycle, the premature lysis of cells, although non-replicating, can be infectious and participate in viral specific toxic effects and increase the specific activity ratio of the resulting agent. Provisionally releases hollow particles. The specific infectivity ratio of the preparation produces the total number of virus particles as measured by biochemical methods (OD260nm, CLHP, PCR, immunoenzyme method, etc.): biological effects (formation of cytolytic phage, cell transduction in culture in solid medium). It is defined as the ratio of the number of viral particles. Practically, for purified formulations, this ratio is determined by calculating the concentration ratio of the particles measured by OD at 260 nm: the concentration of plaque forming units of the formulation. This ratio is 100 or less.

The results show that the process of the present invention makes it possible to obtain viruses of at least equivalent purity to homologs purified by the cesium chloride gradient concentration, in one step, without prior treatment, using the concentrated virus supernatant as the starting material.

Therefore, a first object of the present invention relates to a method for producing a recombinant adenovirus, characterized in that viral DNA is introduced into a capsidated cell culture and the resulting virus is collected after release into the culture supernatant. In contrast to the prior art methods in which viruses are harvested after premature cell lysis performed mechanically or chemically, in the method of the invention, the cells are not lysed by external factors. The culture is continued for a longer period of time and the virus is harvested directly from the supernatant after simultaneous release by the encapsidated cells. The virus according to the invention is thus recovered in the cell supernatant, whereas for the prior art methods it is endogenous, in particular internuclear virus.

Applicants have found that, despite the prolonged incubation duration and the use of large volumes, the method according to the invention makes it possible to produce viral particles in a much better quality. In addition, as described above, this process makes it possible to avoid dissolution steps that are cumbersome at the industrial level and produce a large number of impurities.

The principle of the method is thus based on the collection of the virus released into the supernatant. This method may involve longer incubation times than for the prior art based on cell lysis. As mentioned above, the collection time need not be accurate within half a day. This is essentially determined by the virus release kinetics into the cell supernatant.

The kinetics of virus release can be monitored in a variety of ways. In particular, RP-HPLC, IE-HPLC, semi-quantitative PCR (Example 4.3), staining of dead cells by trypan blue, measurement of release of LDH-type endothelial enzymes, measurement of particles in supernatant by coulter type device or light scattering It is also possible to use analytical methods such as immunological methods (ELISA, RIA, etc.) or bacterial assays in suspension, titration by aggregation in the presence of antibodies.

Preferably, harvesting is performed when at least 50% of the virus is released into the supernatant. The time when 50% of the virus is released can be easily determined by deriving the kinetics according to the method described above. More preferably, harvesting is performed when at least 70% of the virus is released into the supernatant. Particular preference is given to performing collection when at least 90% of the virus is released into the supernatant, ie when the kinetics reach a stable level. The kinetics of virus release is essentially based on the adenovirus replication cycle and can be influenced by certain factors. In particular, it can vary depending on the type of virus used, and in particular the type of deletion occurring in the recombinant viral genome. In particular, deletion of the E3 region appears to delay the release of the virus. Thus, in the presence of the E3 region, the virus can be harvested from 24 to 48 hours post-infection. In contrast, in the absence of the E3 region, longer incubation times appear to be necessary. In this regard, we conducted experiments on the release kinetics of adenoviruses deficient in the E1 and E3 regions in the cell supernatant and found that release began about 4-5 days after infection and continued until approximately 14 days. Release generally reaches a steady state between days 8 and 14, and the titer remains stable for at least 20 days post-infection.

Preferably, in the process of the invention, the cells are incubated for 2 to 14 days. Moreover, release of the virus can be induced by expression of a protein, eg, viral protein, involved in the release of the virus in capsidated cells. Thus, for adenoviruses, release can be modulated by the expression of a killing protein (protein E3-11.6K) encoded by the E3 region of adenovirus, optionally expressed under the control of an inducible promoter. For this reason, more than 50% of the virus can be harvested after 24 to 48 hours infection in the culture supernatant by controlling the virus release time.

In order to recover the virus particles, the culture supernatant is advantageously filtered beforehand. In adenoviruses of about 0.1 μm (120 nm) in size, filtration is performed by membranes that are large enough to pass the virus but have a fine porosity sufficient to retain contaminants. Preferably, the filtration is carried out by a membrane having a porosity of at least 0.2 μm. According to a particularly advantageous embodiment, the filtration is carried out by continuous filtration in a decreasing porous membrane. Particularly good results are obtained by performing filtration on decreasing porosity 10 μm, 1.0 μm and depth filters of 0.8 to 0.2 μm. According to a preferred alternative, the filtration is carried out by tangential microfiltration on flat membranes or hollow fibers. It is possible in particular to use flat millipore membranes or hollow fibers with a porosity of 0.2 to 0.6 μm. The results presented in the Examples show that this filtration step achieves 100% yield (no loss of virus was observed by retaining on the filter with the lowest porosity).

In accordance with another aspect of the present invention, Applicants have developed a method that enables the collection and purification of viruses from the supernatant. To this end, the filtered (or clarified) supernatant is ultrafiltered. This ultrafiltration allows adjustment to supernatant concentration (large volume involved) (i), primary purification of virus (ii) and subsequent preparation of the preparation buffer. According to a preferred embodiment, the supernatant is added to tangential ultrafiltration. Tangential ultrafiltration applies two compartments separated by a membrane with a measured cut-off, solution concentration and fractionation between retentate and filtrate, generation of flow in the retentate compartment of the apparatus and transport membrane pressure between these compartments and filtrate compartments. It is in a ship. The flow is generally produced by a pump in the retentate compartment of the device and the transport membrane pressure can be regulated by a valve for the liquid stream of the retentate circuit or a variable displacement pump for the liquid stream of the filtrate circuit. The flow rate and transport membrane pressure are selected to generate a low shear force (5000 sec ⁻¹ , preferably Reynolds number below 3000 sec ⁻¹ , pressure below 1.0 bar) while avoiding blocking of the membrane. For example, various systems such as spiral membranes (Millipore, Amicon), flat membranes or hollow fibers (Amicon, Millipore, Sartorius, Pall, GF, Sepracor) can be used for ultrafiltration. Adenoviruses having a mass of about 1000 kDa, membranes with a cut-off of 1000, preferably 100 kDa to 1000 kDa, are advantageously used within the framework of the present invention. The use of a membrane with a cut-off greater than 1000 kDa results in significant loss of the virus at this stage. Preferably, a film is used having a cut-off of from 200 to 600 kDa, more preferably from 300 to 500 kDa. The experiments presented in the Examples show that the use of a membrane with a cut-off of 300 kDa allows retention of at least 90% of viral particles while removing contaminants (DNA, proteins in the medium, cellular proteins, etc.) from the medium. The cut-off use of 500 kDa provides the same advantages.

The results presented in the Examples show that this step allows to concentrate the large volume of the supernatant without loss of virus (90% yield) and to produce virus of better quality.

Thus, such ultrafiltration constitutes further purification compared to conventional strategies since at least partly the contaminants having a mass less than cut-off (300 or 500 kDa) are removed. Enhancement of viral product quality is evident when the separation mode is compared after the first ultrafiltration step following the two processes. In conventional processes involving dissolution, the tubes of viral preparation often exhibit a blurred appearance with coagulum (lipids, proteins) that touch the viral band, whereas in the process of the present invention, preparations after release and ultrafiltration Has a band that is already well analyzed from contaminants in the medium that persist on the top. Enhancement of quality is also demonstrated when comparing the ion exchange chromatography profile of the virus obtained by cell lysis against the virus obtained by ultrafiltration as described herein. Moreover, quality can be further enhanced by performing ultrafiltration by diafiltration of the concentrate. This diafiltration is carried out on the same principle as in tangential ultrafiltration and it is possible to completely remove contaminants of size beyond the membrane cut-off while equilibrating the concentrate in the purification buffer.

Furthermore, Applicants also found that such ultrafiltration allows for direct purification of the virus by chromatography on an ion exchange column or by gel permeation chromatography, thus eliminating the need for treatment of the agent prior to chromatography. It has been found that excellent degradation can be obtained. This is not particularly expected and advantageous. In fact, chromatographic purification of viral preparations, as indicated in the literature by Hyughe et al., Cited above, impart mediocre results and further require pretreatment of the virus suspension with benzonase and cyclodextrin.

Specifically, the process according to the invention is characterized in that the virus is thus collected by ultrafiltration.

As mentioned above, the resulting concentrate can be used directly for virus purification. This purification can be accomplished by conventional techniques such as centrifugation on cesium chloride or other ultrafiltration media that allow particles to separate according to size, density or sedimentation coefficient. The results presented in Example 4 show, in fact, that the virus obtained has significant properties. In particular, according to the present invention, cesium chloride is selected from iodixanol, 5,5 '-[(2-hydroxy-1,3-propanediyl) bis (acetylimino)]-bis [N, N'-bis ( 2,3-dihydroxypropyl) -2,4-triiodo-1,3-benzenedicarboxamide], in which the virus settles in equilibrium at a relative density of 1.16 to 1.24 do. The use of such solutions is advantageous because, unlike cesium chloride, they are nontoxic. Moreover, Applicants also advantageously allow the obtained concentrate to also purify the virus directly by ion exchange mechanism or by gel permeation and to obtain excellent degradation of viral particle chromatography peaks without the need for pretreatment. .

According to a preferred embodiment, the virus is thus collected and purified by anion exchange chromatography.

For anion exchange chromatography, cellulose, agarose (sepharose gel), dextran (sephadex gel), acrylamide (cepacryl gel, trisacryl gel), silica (TSK gel-SW gel), poly (styrene- Various types of supports such as divinylbenzene] (Source or Poros gel), ethylene glycol-methacrylate copolymers (Toyopearl HW gel and TSK gel-PW gel), or mixtures (agarose-dextran: superdex gel) Furthermore, in order to enhance the chromatographic resolution, within the framework of the present invention, it is preferable to use a bead-shaped support having the following characteristics:

-Spherical as possible,

-Calibrated diameter (beads that are all the same or as homogeneous as possible), no defects or breakage,

-Minimum possible diameter: beads of 10 μm are described (eg MonoBeads from Pharmacia or TSK from OosoHaas). These values also appear to constitute a lower limit for the diameter of the beads, which must be very high in porosity for the object to be chromatographed inside the beads),

-Stay rigid to withstand pressure.

Moreover, in order to chromatograph adenoviruses that make up objects of extra-large size (100 nm or more in diameter), having a high upper limit of porosity, or even as much as possible, allows the access of viral particles to the functional groups of interest. It is important to use a gel with a high porosity.

Advantageously, the support is chosen alone or as a mixture from agarose, dextran, acrylamide, silica, poly [styrene-divinylbenzene], ethylene glycol-methacrylate copolymers.

For anion exchange chromatography, the support used must be functionalized by implanting groups that can interact with the anionic molecules. More generally, the group consists of amines which may be tertiary or quaternary. For example, by using a tertiary amine such as DEAE, a weak anionic exchanger is obtained. Strong anion exchangers are obtained by using quaternary amines.

Within the framework of the present invention, it is particularly advantageous to use strong anionic exchangers. Thus, chromatographic supports functionalized with quaternary amines as indicated above are preferably used according to the invention. Among the supports functionalized with quaternary amines, mention may be made of resins Source Q, Mono Q, Q Sepharose, Poros HQ and Poros QE, resins of the Fractogel TMAE type and Toyopearl Super Q resins as examples.

Preferred examples of resins that can be used within the framework of the invention are Source, in particular Source Q, for example 15 Q (Pharmacia), MonoBeads, for example Q (Pharmacia), Poros HQ and Poros OE type resins. . MonoBeads supports (bead diameter 10 ± 0.5 μm) have been commercially available for more than 10 years, and Source (15 μm) or Poros (10 μm or 20 μm) resins for about 5 years. Source or Poros supports exhibit the advantage of having a very wide internal pore distribution (they range from 20 nm to 1 μm), thus allowing the passage of very large objects through the beads. In addition, they provide very little resistance to circulation or liquid through the gel (and therefore very little pressure) and are very hard. Therefore, the transport of solutes to the functional groups to interact is very rapid. Applicants are particularly important for adenoviruses where dispersion is slow due to their size.

The results presented in the Examples show that adenoviruses can be purified from concentrations in a single anion-exchange chromatography step with good purification yields (compared to the value of 49% reported by Huyghes et al. At tdu). have. In addition, the results presented exemplify that the adenoviruses obtained have high infectivity and therefore have the required properties for therapeutic use. Particularly advantageous results are obtained with strong anion exchangers, ie functionalized with quaternary amines, in particular with resin Source Q. Resin Source Q15 is particularly preferred.

In this regard, another subject of the present invention relates to a method for purifying recombinant adenovirus from a biological medium, comprising the step of purifying by strong anion-exchange chromatography.

In such a modification, the biological medium may be a suspension of virus producing capsidated cells, a lysate of virus producing capsidated cells or a virus purification solution.

Preferably, chromatography is performed on a support functionalized with quaternary amines. Also in a preferred mode, the support is selected alone or as a mixture from agarose, dextran, acrylamide, silica, poly [styrene-divinylbenzene], ethylene glycol-methacrylate copolymer.

A particularly advantageous embodiment is characterized in that the chromatography is carried out in a Source Q resin, preferably Q15.

In addition, the method described above is advantageously carried out using a suspension of producing cells and comprises a preliminary ultrafiltration step. This step is advantageously carried out under the conditions described above and in particular it is tangential ultrafiltration in a membrane with a cut of 300 to 500 kDa.

In another embodiment of the method of the invention, the virus is obtained and purified by gel permeation chromatography.

Gel permeation can be performed directly on supernatants, concentrates, or viruses derived from anion-exchange chromatography. The support mentioned for anion-exchange chromatography can be used in this step without being functionalized.

In this regard, preferred supports are agarose (Sepharose gel), dextran (Sephadex gel), acrylamide (Sephacryl gel, Trisacryl gel), silica (TSK gel-SW gel), ethylene glycol-methacrylate copolymer (Toyopearl HW) Gel and TSK gel-PW gel), or a mixture (agarose-dextran: Superdex gel). Particularly preferred supports are

-Superdex 200HR (Pharmacia)

Sephacryl S-500HR, S-1000HR or S-2000 (Pharmacia)

-TSK G6000 PW (TosoHaas).

Therefore, the preferred method according to the invention comprises ultrafiltration followed by anion-exchange chromatography.

Preferred methods include ultrafiltration followed by anion-chromatography followed by gel permeation chromatography.

A modification of the invention relates to a method for purifying adenovirus from a biological medium comprising a first step of ultrafiltration, a second step of dilution or dialysis and a third step of anion-exchange chromatography. Preferably, in this variant, the first step is carried out by rapid ultrafiltration of cesium chloride gradient. The term rapid means ultrafiltration in the range of about 0.5 to 4 hours. During the second step, the virus is diluted or dialyzed against the buffer to facilitate injection into the chromatography gel and removal of the ultrafiltration medium. The third step is carried out using anions, preferably strong anion-exchange chromatography, as described above. In a typical experiment, starting with the virus obtained in the supernatant (or optionally intracellularly), the first ultrafiltration is run with cesium chloride (as in Example 3). Next, after a simple dilution of the sample (eg, with 10 volumes of buffer) or after a simple dilution in buffer, the sample is subjected to ion-exchange chromatography (as in Example 5.1). The advantage of this variant of the method of the present invention stems from the fact that it uses a total of two different virus isolation modalities (density and surface charge), which can possibly lead the virus to a level of query that combines the performance of the two methods. . The chromatographic step also makes it possible to simultaneously remove the medium used for ultrafiltration (eg cesium chloride or other equivalent medium as described above).

Another subject of the invention is iodixanol, 5,5 '-[2-hydroxy-1,3-propanediyl) bis (acetylimino)] bis [N, N'-bis (2) for adenovirus purification , 3-dihydroxypropyl) -2,4,6-triiodo-1,3-benzenedicarboxamide].

In order to carry out the methods of the invention, various adenovirus capsidated cells can be used. In particular, the encapsidated cells can be prepared from a variety of pharmaceutically useful cells, ie those that can be cultured under industrially acceptable conditions but do not have recognized pathological properties. They can establish cell lines or first cultures and in particular human retinoblastoma, human lung cancer cells, or embryonic kidney cells. They can advantageously be cells of human origin that can be infected by adenoviruses. In this regard, KB, Hela, 293, Vero, gmDBP6, HER, A549, HER cells and the like can be mentioned.

KB's cell line is derived from human epithelial carcinoma. It is easy to access under conditions that allow ATCC (ref. CCL17) and its culture. Human cell line Hela is derived from human epithelial carcinoma. It is also easy to access under conditions that allow ATCC (ref. CCL2) and its culture. Cell line 293 is human embryonic kidney cells. See, eg, Graham et al., J. Gen. Virol. 36 (1977) 59]. This cell line contains in particular the left part of the human adenovirus Ad5 (12%) genome integrated in its genome. The cell line gm DBP6 (Brough et a., Virology 190 (1992) 624) consists of Hela cells carrying adenovirus E2 gene under the control of MMTV LTR.

They may also be cells of dog origin (BHK, MDCK, etc.). In this regard, the MDCK cell line of cats is preferred. Conditions for culturing MDCK are described in particular in Macatney et al., Science 44 (1988) 9.

Various capsidated cell lines are described in the literature and are mentioned in the Examples. These are advantageously cells which trans complement the adenovirus E1 function. More preferably, they are cells that trans-complement adenovirus El and E4 or El and E2a functions. Such cells are preferably derived from renal or retinal cells, or human lung carcinoma.

Accordingly, the present invention provides a method of producing a particularly advantageous recombinant adenovirus. This method is suitable for the production of recombinant viruses which are defective in one or more regions, in particular viruses which are defective for the El region or for the El and E4 regions. In addition, as noted above, this can be applied to the production of adenoviruses of various serotypes.

According to a particularly advantageous mode, the method of the present invention is used for the production of recombinant adenovirus in which the El region is inactivated by deletion of the PvuII-BglII fragment stretching nucleotide 3328 to nucleotide 3328 in the Ad5 adenovirus sequence. Such sequences are easy to access in literature and databases (see in particular Genebank No. M73260). In another preferred embodiment, the El region is inactivated by the deletion of a HindfII-Sau3A fragment that stretches nucleotide 3446 at nucleotide 382. In certain modalities, the method allows for the generation of a vector comprising deletions throughout the E4 region. This can be done by excision of the MaeII-MscI fragment corresponding to 32720 at nucleotides 35935. In another form, only the functional site of E4 is deleted. This portion includes at least ORF3 and ORF6 frames. By way of example, such a reading frame may be deleted from the genome in the form of pvuII-AluI and BglII-PvuII fragments, respectively, corresponding to nucleotides 34801 at 34329 and 34115 at 33126, respectively. Deletion of the E4 region of virus Ad2 dl808 or virus Ad5 dl1004, Ad5 dl1007, Ad5 dl1011 or Ad5 dl1014 can also be used within the framework of the invention. In this regard, the cells of the present invention are particularly advantageous for the production of viruses comprising deletions in the inactive El region and in the E4 region of the type present in the genome of Ad5 dl1014, ie E4 ^- viruses which convert the reading frame ORF4.

As pointed out above, deletion of the El region advantageously includes all or a portion of the El and El regions. This deletion should be sufficient to make the virus impossible for spontaneous replication within the cell. Some of the El regions deleted in the adenovirus according to the invention advantageously comprise nucleotides 454 at 3328 or 382 at 3446.

The corresponding positions refer to wild type Ad5 adenovirus sequences that are published and accessible on a database. Although minor modifications may exist between the various adenovirus serotypes, this position is generally applicable to the construction of recombinant adenoviruses according to the invention from the serotypes, and in particular adenoviruses Ad2 and Ad7.

In addition, the resulting adenovirus may have other modifications to this genome. In particular, other regions may be deleted to increase the ability of the virus and to reduce the side effects linked to the expression of viral genes. Thus, all or part of the E3 or Iva2 region may be particularly deleted. However, with respect to the E3 region, it may be particularly advantageous to switch the portion encoding the gp19K protein. Indeed such proteins make it possible for adenovirus vectors to (i) limit their action and (ii) not be the subject of an immune response that may have undesirable side effects. According to certain modalities, the E3 region is deleted and the sequence encoding the gp19K protein is reintroduced under the control of a heterologous promoter.

As noted above, adenoviruses constitute vectors for gene delivery that are highly efficient for gene and cell therapeutic applications. To this end, heterologous nucleic acids intended for delivery and / or expression to a cell, organ or organism can be inserted into its genome. Such sequences may contain one or more therapeutic genes, eg, one or more therapeutic genes whose transcription and possible translation in a target cell produces a product having a therapeutic effect. Among the therapeutic products, enzymes, blood derivatives, hormones, lymphokines: interleukin, interferon, TNF, etc. (FR 9203120), growth factors, neurotransmitters or precursors or synthetases thereof, nutritional factors: BDNF, CNTF, NGF , IGF, GMF, aFGF, bFGF, NT3, NT5 and the like; Apolipoproteins: ApoAI, ApoAIV, ApoE, etc. (WO 94/25073), dystrophin or minidystrophin (WO 93/06223), tumor suppressor genes: p53, Rb, Rap1A, DCC, k-rev, etc. (WO 94/24297) , Gene coding factors involved in coagulation: Factors VII, VIII, IX, etc. Suicide genes: thymidine kinase, Shiosin deaminase, etc., or all or part of natural or artificial immunoglobulins (Fab, ScFv et al., WO94 / 29446) may be mentioned. The therapeutic gene may also be an antisense gene or sequence whose expression in the target cell allows for regulation of gene expression or cellular mRNA transcription. Such sequences can, for example, be transcribed into RNA complementary to cellular mRNA in the target cell and thus inhibit translation into proteins according to the techniques described in patent EP 140 308. The therapeutic gene may also be a gene encoding an antigenic peptide capable of generating an immune response in humans for vaccine production. These may be antigen peptides specific for the Epstein-Barr virus, HIV virus, Hepatitis B virus (EP 185 573), Pseudo-Raviz virus or for tumors (EP 259 212).

In general, the heterologous nucleic acid sequence also includes a transcriptional promoter region that is functional in the infected cell and the region located in the gene 3 ′ and which specializes in transcriptional end signals and polyadenylation sites. All of these elements constitute an expression cassette. With regard to the promoter region, this may be a promoter region which is naturally responsible for the expression of the gene under consideration if the promoter can be functionalized in infected cells. It may also be a region of different origin (which is responsible for the expression of other proteins, or even synthetic). In particular, they may be promoter sequences or elicited promoter sequences of eukaryotic or viral genes that stimulate or inhibit transcription of the gene in a particular way or otherwise or in an inducible way or otherwise. By way of example, it may be a promoter sequence derived from the genome of the cell or virus genome desired to be infected, in particular adenovirus MLP, E1A gene, RSV-LTR, CMV promoter and the like. Among eukaryotic promoters, ubiquitous promoters (HPRT, bimentin, α-actin, tubulin, etc.), promoters of intermediate filaments (desmin, neurofilament, keratin, GFAP, etc.), promoters of therapeutic genes (MDR, CFTR, factor VIII) Types, etc.), tissue-specific promoters (pyruvate kinases, borrowers, promoters for visceral fatty acid-binding proteins, promoters for α-actin of smooth muscle cells, promoters specific for the liver; Apo AI, Apo AII, human albumin, etc.) or Alternatively, promoters that respond to stimulation (steroid hormone receptors, retinoic acid receptors, etc.) may also be mentioned. Such expression sequences can also be modified by addition of activation or regulatory sequences or sequences that allow tissue-specific or predominant expression. In addition, if the inserted nucleic acid does not contain an expression sequence, it may be inserted into the genome downstream of the viral deletion of this sequence.

In addition, the heterologous nucleic acid sequence may contain a signal sequence that, in particular, upstream of the therapeutic gene, directs the therapeutic product synthesized in the secretory pathway of the target cell. Such signal sequences may be natural signal sequences for therapeutic products, but they may also be other functional signal sequences or artificial signal sequences.

Expression cassettes for therapeutic genes can be inserted into various sites of the recombinant adenovirus genome, according to techniques described in the prior art. This can be inserted above all at the level of E1 deletion. It can also be inserted at the level of the E3 region as addition or substitution of sequences. It can also be located at the level of the deleted E4 region.

The invention also relates to the preparation of the purified virus obtained according to the method of the invention and to a pharmaceutical composition comprising at least one defective recombinant adenovirus produced according to the invention. The pharmaceutical compositions of the present invention may be formulated for topical, oral, parenteral, nasal, intravenous, intramuscular, subcutaneous, intraocular or transdermal administration and the like.

Preferably, the pharmaceutical composition contains a pharmaceutically acceptable vehicle for injectable formulation. They are particularly suited to the composition of the injectable solution upon addition of saline (mono- or disodium phosphate, sodium, potassium, calcium or magnesium chloride, or mixtures of these salts), sterile or isotonic solutions, or sterile water or physiological saline, if desired. Acceptable drying, in particular freeze-drying compositions. For example, other excipients such as hydrogels can be used. Such hydrogels can be prepared from biocompatible and noncytotoxic polymers (homo or hetero). Such polymers are described, for example, in WO 93/08845. Some of these are commercially available, for example those obtained from ethylene and / or propylene oxide in particular. The viral dose used for injection can be adjusted according to various parameters, in particular the dosage form used, the relevant route, the gene to be expressed or the desired duration of treatment. In general, the recombinant adenovirus according to the invention is formulated and administered in a dosage form of 10 ⁴ to 10 ¹⁴ pfu, preferably 10 ⁶ to 10 ¹⁰ pfu. The term pfu (plaque forming unit) corresponds to the degree of infection of an adenovirus solution and is measured by infecting a suitable cell culture and generally measuring the number of infected cell plaques after 15 days. Techniques for measuring pfu titration of viral solutions are well described in the literature.

Depending on the therapeutic gene, the virus produced in this way may be a genetic disease (malnutrition, gallbladder fibrosis, etc.), neurodegenerative diseases (Alzheimer's, Parkinson's, ALS, etc.), cancers, diseases associated with coagulation disorders or lipoprotein disorders, viral infections It can be used for the treatment or prophylaxis of many diseases, including diseases associated with (hepatitis, AIDS, etc.).

The invention will be described more fully with the aid of the following examples which should be considered as illustrative and not restrictive.

Claims (32)

A method for producing a recombinant adenovirus, characterized in that viral DNA is introduced into a capsidated cell culture and the resulting virus is collected after release into the supernatant. The method of claim 1, wherein the harvesting is performed when at least 50% of the virus is released into the supernatant. The method of claim 1, wherein the harvesting is performed when at least 70% of the virus is released into the supernatant. The method of claim 1, wherein the harvesting is performed when at least 90% of the virus is released into the supernatant. The method of claim 1, wherein the virus is harvested by ultrafiltration. 6. The method of claim 5 wherein the ultrafiltration is tangential ultrafiltration. 7. Method according to claim 5 or 6, characterized in that ultrafiltration is carried out on the membrane with a cut off of 1000 kDa or less. The method of claim 1 wherein the virus is harvested by anion exchange chromatography. 9. The method of claim 8, wherein the anion exchange chromatography is strong anion exchange chromatography. 10. The method of claim 9, wherein the strong anion exchange chromatography is performed on a support selected from resins Source Q, Mono Q, Q Sepharose, Poros HQ and Poros QE, resins of the Fractogel TMAE type and Toyopearl Super Q. The method of claim 1, wherein the virus is harvested by gel permeation chromatography. Gel permeation chromatography was performed on gel Sephacryl S-500 HR, Sephacryl S-1000 SF, Sephacryl S-1000 HR, Sephacryl S-2000, Superdex 200 HR, Sepharose 2B, 4B or 6B and TSK G6000 PW. Characterized in that it is carried out on a selected support. 2. The method of claim 1, wherein the virus is harvested by ultrafiltration followed by anion exchange chromatography. The method according to claim 13, wherein the virus is collected by ultrafiltration followed by anion exchange chromatography followed by gel permeation chromatography. The method according to any one of claims 1 to 14, wherein the capsidated cells are cells that trans complement the adenovirus E1 function. The method of claim 15, wherein the capsidated cells trans complement complement adenovirus E1 and E4 functions. 16. The method of claim 15, wherein the capsidated cells trans complement complement adenovirus E1 and E2a functions. 18. The method of any one of claims 15 to 17, wherein the cells are cells from embryonic human kidney cells, human retinal cells or human carcinoma. A method for purifying recombinant adenovirus from a biological medium, comprising the step of purifying by strong anion exchange chromatography. 20. The method of claim 19, wherein the biological medium is a supernatant of capsidated cells producing a virus. 20. The method of claim 19, wherein the biological medium is a lysate of capsidated cells that produce a virus. 20. The method of claim 19, wherein the biological medium is a prepurification solution of the virus. 20. The method of claim 19, wherein the chromatography is performed on a support functionalized with a quaternary amine. 24. The method of claim 23, wherein the support is selected from agarose, dextran, acrylamide, silica, poly [styrene-divinylbenzene], ethylene glycol-methacrylate copolymer and used alone or in a mixture thereof. How to. 25. The method of claim 24, wherein the chromatography is performed on a support selected from Resin Source Q, Mono Q, Q Sepharose, Poros HQ, Poros QE, Fractogel TMAE, and Toyopearl Super Q. The process according to claim 25, wherein the chromatography is carried out on a Source Q resin, preferably Q15. 20. The method of claim 19, comprising a preliminary ultrafiltration step. 28. The method of claim 27, wherein the ultrafiltration is tangential ultrafiltration in a membrane having a cut off of 300 to 500 kDa. Purified virus preparation obtained according to the method of claim 1. A pharmaceutical composition comprising the viral preparation according to claim 29 and a pharmaceutically acceptable vehicle. Iodixanol, 5,5 '-[(2-hydroxy-1,3-propanediyl) bis (acetylimino)] bis [N, N'-bis (2,3-dihydroxypropyl) -2 , 4,6-triiodo-1,3-benzenecarboxamide] for adenovirus purification. A method for purifying adenovirus from biological media, comprising a first step of ultracentrifugation, a second step of dilution or dialysis, and a third step of anion exchange chromatography.